Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin
Jessica Sable, Tura Patterson, Gary Tarpley, Poncho Meisenheimer, Robert B. Kargbo, Alexander M. Sherwood, Andrew J. Walker, Nicholas V. Cozzi, Raymond E. Dagger, Kelsey O’hern, Kristi W. Kaylo
ACS Omega July 1, 2020 DOI: 10.1021/acsomega.0c02387 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Methodological report Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Phosphorylation |
| Citations | 41 |
| Key points | A second-generation kilogram-scale synthesis of psilocybin was developed that features an optimized Speeter-Anthony tryptamine synthesis and direct phosphorylation of psilocin with phosphorous oxychloride, producing over one kilogram of high-purity psilocybin under cGMP. |
Abstract
A second-generation kilogram-scale synthesis of the psychedelic tryptamine psilocybin has been developed. The synthesis was designed to address several challenges first encountered with the scale-up of previously described literature procedures, which were not optimized for providing consistent yield and purity of products, atom economy, or being run in pilot plant-scale reactors. These challenges were addressed and circumvented with the design of the second-generation route, which featured an optimized cGMP large-scale Speeter-Anthony tryptamine synthesis to the intermediate psilocin with improved in-process control and impurity removal over the three steps. Psilocin was subsequently phosphorylated directly with phosphorous oxychloride for the first time, avoiding a tedious and poor atom economy benzyl-protecting group strategy common to all previously described methods for producing psilocybin. In this report, the challenges encountered in a 100 g scale first-generation literature-based synthesis are highlighted, followed by a detailed description of the newly developed second-generation synthesis to provide over one kilogram of high-purity psilocybin under cGMP.
Citations in the library
Cited by 33
- Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. Fungal biology April 1, 2022
- Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use ACS Omega December 2, 2020
- A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond Biotechnology Advances August 31, 2023
- Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report Heliyon December 1, 2022
- Psychedelic-like Activity of Norpsilocin Analogues ACS Chemical Neuroscience January 8, 2024
and 28 more in the library
Cites 19
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
and 14 more in the library